Nirvana Life Sciences Inc.
NIRVF
$0.08
-$0.01-8.07%
OTC PK
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.67% | -31.33% | -44.18% | -60.81% | -54.48% |
| Depreciation & Amortization | -163.70% | -163.70% | -163.70% | -82.63% | -60.18% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.92% | -44.07% | -56.21% | -63.25% | -55.06% |
| Operating Income | 26.92% | 44.07% | 56.21% | 63.25% | 55.06% |
| Income Before Tax | 48.40% | 58.73% | 68.49% | 63.55% | 52.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.40% | 58.73% | 68.49% | 63.55% | 52.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -120.00% | -111.76% | -113.64% | -88.57% | -57.14% |
| Net Income | 48.20% | 58.58% | 68.37% | 63.47% | 52.64% |
| EBIT | 26.92% | 44.07% | 56.21% | 63.25% | 55.06% |
| EBITDA | 53.90% | 51.31% | 55.17% | 62.40% | 52.64% |
| EPS Basic | 61.96% | 70.69% | 75.55% | 70.71% | 63.87% |
| Normalized Basic EPS | 48.17% | 62.38% | 72.12% | 76.22% | 67.72% |
| EPS Diluted | 61.96% | 70.69% | 75.55% | 70.71% | 63.87% |
| Normalized Diluted EPS | 48.17% | 62.38% | 72.12% | 76.22% | 67.72% |
| Average Basic Shares Outstanding | -10.78% | 331.94% | 247.12% | 259.90% | 292.18% |
| Average Diluted Shares Outstanding | -10.78% | 331.94% | 247.12% | 259.90% | 292.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |